21:24 , Nov 10, 2017 |  BC Week In Review  |  Company News

iPharma gets rights to Boehringer's FAK inhibitor

Boehringer Ingelheim GmbH (Ingelheim, Germany) granted iPharma Ltd. exclusive, worldwide rights to develop and commercialize BI 853520, a focal adhesion kinase inhibitor. iPharma is a JV formed in August 2016 by BioLineRx Ltd. (Tel Aviv:BLRX;...
23:02 , Nov 3, 2017 |  BC Extra  |  Company News

iPharma gets rights to Boehringer's FAK inhibitor

Boehringer Ingelheim GmbH (Ingelheim, Germany) granted iPharma Ltd. exclusive, worldwide rights to develop and commercialize BI 853520, a focal adhesion kinase inhibitor. iPharma is a JV formed in August 2016 by BioLineRx Ltd. (Tel Aviv:BLRX;...